The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study to evaluate the safety and efficacy of switchable CAR-T cell therapy with FY001 and CART001 in patients with refractory CD20-positive B-cell non-Hodgkin lymphoma (EPOC1803).
 
Junichiro Yuda
Research Funding - Abbvie; Amgen; AstraZeneca; Brighpath Bio; Bristol-Myers Squibb/Celgene; Celeid Therapeutics; Chugai Pharma; Daiichi Sankyo; Genmab; Incyte; Janssen; Mitsubishi Tanabe; MSD; Novartis; Sanofi; Sumitomo Pharma; Takeda
 
Yukiko Ishiguro
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Kyowa Kirin; Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Incyte; Noile-Immune Biotech, Inc; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); Incyte (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Kyowa Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte
 
Tetsuya Nakatsura
Stock and Other Ownership Interests - Logomix Inc; Noile-Immune Biotech Inc; Optieum Biotechnologies Inc.
Research Funding - BrightPath Biotheraputics; Daicel; Heartseed; LogoMix; MaxCyte, Inc; MEDINET Co., Ltd; NA Vaccine Institute CO., LTD; Napajen Pharma; Ono Pharmaceutical; Optieum Biotechnologies Inc.; Resonac Corporation; Takara Bio; Thyas
Patents, Royalties, Other Intellectual Property - MEDINET Co., Ltd; Noile-Immune Biotech Inc.; OncoTherapy Science; Resonac Corporation; Takara Bio; Thyas Co., Ltd.
 
Toshihiro Suzuki
No Relationships to Disclose
 
Hirotaka Nakamura
No Relationships to Disclose
 
Takashi Ikeno
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Nozomu Fuse
Honoraria - Astellas Pharma; AstraZeneca
 
Akihiro Sato
Honoraria - Astellas Pharma; AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nanami Nakamura
Employment - Noile-Immune Biotech, Inc
 
Yukimi Sakoda
Stock and Other Ownership Interests - Noile-Immune Biotech, Inc
Consulting or Advisory Role - Noile-Immune Biotech, Inc
Research Funding - Noile-Immune Biotech, Inc
 
Toshihiko Doi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - A2 Healthcare; Amgen; Boehringer Ingelheim; Chugai Pharma; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; Mitsubishi Tanabe Pharma; Noil-Immune Biotech; Oncolys BioPharma; Rakuten Medical; SHIONOGI; Sumitomo Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); RIN Institute (Inst); SHIONOGI (Inst); Taiho Pharmaceutical (Inst)
 
Koji Tamada
Leadership - Noile-Immune Biotech, Inc
Stock and Other Ownership Interests - Noile-Immune Biotech, Inc
Honoraria - Chugai Pharma; Ono p